Super-Sized flu shot tested for Seniors' heart and lung protection
NCT ID NCT04137887
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study compared a high-dose flu vaccine to the standard-dose shot in over 33,000 adults aged 65 and older. The goal was to see if the high-dose version could better prevent hospitalizations for heart and lung problems. The trial was terminated early, so the full picture is not available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- High-dose quadrivalent influenza vaccine (Efluelda®)
- What this could lead to
- If successful, this could show that a stronger flu shot offers better protection against serious heart and lung complications in older adults.
- What could go wrong
- The trial was terminated early, so results are limited. It is unclear if the high-dose vaccine is truly superior for preventing hospitalizations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLUENZA (HEALTHY VOLUNTEERS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Investigational Site Number 2469999
Tampere, 33520, Finland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a nasal spray flu shot at home beat the needle?
- Flu transmission secrets under the microscope in new human trial
- Scientists create controlled flu infection model to speed up vaccine testing
- New study to monitor High-Dose flu shot safety in seniors
- New flu vaccine shows promise in south korean trial
- Super-Sized flu shot shows promise for seniors